Hospital Healthcare Europe

Impact of early CDK4/6 inhibitor use on survival and toxicity in advanced breast cancer

Using CDK4/6 inhibitors as first-line therapy in advanced breast cancer does not improve overall survival compared with ...
ascopubs.org

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma

Cyclin-dependent kinase (CDK)4/6 inhibitors are approved for the treatment of breast cancer, and they have more recently been used in patients with well ...
The American Journal of Managed Care

Managing Patients with CDK 4/6 Inhibitor-Resistance

Dr Hanna drives a discussion regarding breast cancer treatments that have developed resistance to CDK 4/6 inhibitors. Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC: Let’s say a patient wasn’t compliant ...
BioWorld

Roche patent describes new CDK8/cyclin C inhibitors

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered new heteroarylphenyl ether derivatives acting as cyclin-dependent kinase CDK8/cyclin C inhibitors. As such, they are reported to be ...
VentureBeat

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...